UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Second generation S1P pathway modulators: Research strategies and clinical developments

Biochimica et biophysica acta, 2014-05, Vol.1841 (5), p.745-758

2014

Volltextzugriff (PDF)

Impact of Siponimod on Enteric and Central Nervous System Pathology in Late-Stage Experimental Autoimmune Encephalomyelitis

International journal of molecular sciences, 2022-11, Vol.23 (22), p.14209

2022

Volltextzugriff (PDF)

Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration

Frontiers in immunology, 2022-07, Vol.13, p.814064

2022

Volltextzugriff (PDF)

Siponimod (BAF312) penetrates, distributes, and acts in the central nervous system: Preclinical insights

Multiple sclerosis journal - experimental, translational and clinical, 2021-10, Vol.7 (4), p.20552173211049168-20552173211049168

2021

Volltextzugriff (PDF)

Pharmacological Inhibition of MALT1 Protease Leads to a Progressive IPEX-Like Pathology

Frontiers in immunology, 2020-04, Vol.11, p.745

2020

Volltextzugriff (PDF)

Siponimod is a Functional Agonist for the S1P5 Receptor (P3.404)

Neurology, 2018-04, Vol.90 (15_supplement)

2018

Volltextzugriff (PDF)

Pathophysiological Consequences of a Break in S1P1-Dependent Homeostasis of Vascular Permeability Revealed by S1P1 Competitive Antagonism

PloS one, 2016-12, Vol.11 (12), p.e0168252-e0168252

2016

Volltextzugriff (PDF)

Central Versus Peripheral Drug Exposure Ratio, a Key Differentiator for Siponimod Over Fingolimod?

Neurology and therapy, 2023-08, Vol.12 (4), p.1187-1203

2023

Volltextzugriff (PDF)

Partial deficiency of sphingosine-1-phosphate lyase confers protection in experimental autoimmune encephalomyelitis

PloS one, 2013-03, Vol.8 (3), p.e59630-e59630

2013

Volltextzugriff (PDF)

Meta-analysis for Neurofilament Light Chain as a Biomarker in Mouse Experimental Autoimmune Encephalomyelitis Studies (S17.008)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

Comparative Pharmacology of Ofatumumab vs Ocrelizumab in Humanized CD20 Transgenic Mice (S9.007)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

Siponimod Penetrates, Distributes and Acts on the Central Nervous System: Translational Insights (3973)

Neurology, 2020-04, Vol.94 (15_supplement)

2020

Volltextzugriff (PDF)

Siponimod: From Understanding Mode of Action to Differentiation Versus Fingolimod (1536)

Neurology, 2020-04, Vol.94 (15_supplement)

2020

Volltextzugriff (PDF)

Reduced cardiac side-effect potential by introduction of polar groups: Discovery of NIBR-1282, an orally bioavailable CCR5 antagonist which is active in vivo

Bioorganic & medicinal chemistry, 2008-03, Vol.18 (6), p.2000-2005

2008

Volltextzugriff (PDF)

Siponimod Demonstrates Pro-remyelination Effects in the Mouse Cuprizone-Intoxication Model (2503)

Neurology, 2021-04, Vol.96 (15_supplement)

2021

Volltextzugriff (PDF)

Blockade of CD40–CD154 pathway interactions suppresses ectopic lymphoid structures and inhibits pathology in the NOD/ShiLtJ mouse model of Sjögren’s syndrome

Annals of the rheumatic diseases, 2019-07, Vol.78 (7), p.974-978

2019

Volltextzugriff (PDF)

Gene expression profiling of immunomagnetically separated cells directly from stabilized whole blood for multicenter clinical trials

Clinical and translational medicine, 2014-11, Vol.3 (1), p.1-13

2014

Volltextzugriff (PDF)

Rationale for Use of Sphingosine-1-Phosphate Receptor Modulators in COVID-19 Patients: Overview of Scientific Evidence

Journal of interferon & cytokine research, 2023-06, Vol.43 (6), p.246-256

2023

Volltextzugriff (PDF)

Pharmacokinetic/Pharmacodynamic Characterization of Siponimod (BAF312) in Blood versus Brain in Experimental Autoimmune Encephalomyelitis Mice (P2.2-066)

Neurology, 2019-04, Vol.92 (15_supplement)

2019

Volltextzugriff (PDF)

Optimization of the In Vivo Potency of Pyrazolopyrimidine MALT1 Protease Inhibitors by Reducing Metabolism and Increasing Potency in Whole Blood

Journal of medicinal chemistry, 2020-12, Vol.63 (23), p.14594-14608

2020

Volltextzugriff (PDF)

Discovery of Potent, Highly Selective, and In Vivo Efficacious, Allosteric MALT1 Inhibitors by Iterative Scaffold Morphing

Journal of medicinal chemistry, 2020-12, Vol.63 (23), p.14576-14593

2020

Volltextzugriff (PDF)

Malt1 Protease Deficiency in Mice Disrupts Immune Homeostasis at Environmental Barriers and Drives Systemic T Cell-Mediated Autoimmunity

The Journal of immunology (1950), 2019-12, Vol.203 (11), p.2791-2806

2019

Volltextzugriff (PDF)

Long-Term Fingolimod Treatment Does Not Impair Immune Memory in a Preclinical Immunization Model (P5.317)

Neurology, 2016-04, Vol.86 (16_supplement)

2016

Volltextzugriff (PDF)

Requirement of Mucosa‐Associated Lymphoid Tissue Lymphoma Translocation Protein 1 Protease Activity for Fcγ Receptor–Induced Arthritis, but Not Fcγ Receptor–Mediated Platelet Elimination, in Mice

Arthritis & rheumatology (Hoboken, N.J.), 2020-06, Vol.72 (6), p.919-930

2020

Volltextzugriff (PDF)

1 – 25 von 54

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(53)
Tagungsberichte
(1)

Sprache

Englisch
(54)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Second generation S1P pathway modulators: Research strategies and clinical developments

Impact of Siponimod on Enteric and Central Nervous System Pathology in Late-Stage Experimental Autoimmune Encephalomyelitis

Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration

Siponimod (BAF312) penetrates, distributes, and acts in the central nervous system: Preclinical insights

Pharmacological Inhibition of MALT1 Protease Leads to a Progressive IPEX-Like Pathology

Siponimod is a Functional Agonist for the S1P5 Receptor (P3.404)

Pathophysiological Consequences of a Break in S1P1-Dependent Homeostasis of Vascular Permeability Revealed by S1P1 Competitive Antagonism

Central Versus Peripheral Drug Exposure Ratio, a Key Differentiator for Siponimod Over Fingolimod?

Partial deficiency of sphingosine-1-phosphate lyase confers protection in experimental autoimmune encephalomyelitis

Meta-analysis for Neurofilament Light Chain as a Biomarker in Mouse Experimental Autoimmune Encephalomyelitis Studies (S17.008)

Comparative Pharmacology of Ofatumumab vs Ocrelizumab in Humanized CD20 Transgenic Mice (S9.007)

Siponimod Penetrates, Distributes and Acts on the Central Nervous System: Translational Insights (3973)

Siponimod: From Understanding Mode of Action to Differentiation Versus Fingolimod (1536)

Reduced cardiac side-effect potential by introduction of polar groups: Discovery of NIBR-1282, an orally bioavailable CCR5 antagonist which is active in vivo

Siponimod Demonstrates Pro-remyelination Effects in the Mouse Cuprizone-Intoxication Model (2503)

Blockade of CD40–CD154 pathway interactions suppresses ectopic lymphoid structures and inhibits pathology in the NOD/ShiLtJ mouse model of Sjögren’s syndrome

Gene expression profiling of immunomagnetically separated cells directly from stabilized whole blood for multicenter clinical trials

Rationale for Use of Sphingosine-1-Phosphate Receptor Modulators in COVID-19 Patients: Overview of Scientific Evidence

Pharmacokinetic/Pharmacodynamic Characterization of Siponimod (BAF312) in Blood versus Brain in Experimental Autoimmune Encephalomyelitis Mice (P2.2-066)

Deficiency of MALT1 paracaspase activity results in unbalanced regulatory and effector T and B cell responses leading to multiorgan inflammation

Optimization of the In Vivo Potency of Pyrazolopyrimidine MALT1 Protease Inhibitors by Reducing Metabolism and Increasing Potency in Whole Blood

Discovery of Potent, Highly Selective, and In Vivo Efficacious, Allosteric MALT1 Inhibitors by Iterative Scaffold Morphing

Malt1 Protease Deficiency in Mice Disrupts Immune Homeostasis at Environmental Barriers and Drives Systemic T Cell-Mediated Autoimmunity

Long-Term Fingolimod Treatment Does Not Impair Immune Memory in a Preclinical Immunization Model (P5.317)

Requirement of Mucosa‐Associated Lymphoid Tissue Lymphoma Translocation Protein 1 Protease Activity for Fcγ Receptor–Induced Arthritis, but Not Fcγ Receptor–Mediated Platelet Elimination, in Mice

Suchergebnisse filtern